ATAI - Atai buys 35.5% stake in psychedelic drug developer stock rallies 18%
2024-01-04 15:05:54 ET
More on ATAI Life Sciences
- Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value
- Atai Life Sciences climbs on Phase 1 data for ecstasy candidate
- Seeking Alpha’s Quant Rating on ATAI Life Sciences
- Historical earnings data for ATAI Life Sciences
- Financial information for ATAI Life Sciences
For further details see:
Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18%